Trinity Biotech Announces Appointment Of Louise Tallon As Chief Financial Officer; Des Fitzgerald Will Continue As Interim CFO Until Late July 2024; Reiterates Financial Guidance And Intend To Achieve ~$20M Of Annualized Run-Rate EBITDASO On...
Trinity Biotech Announces Appointment Of Louise Tallon As Chief Financial Officer; Des Fitzgerald Will Continue As Interim CFO Until Late July 2024; Reiterates Financial Guidance And Intend To Achieve ~$20M Of Annualized Run-Rate EBITDASO On...
Trinity Biotech Announces Appointment Of Louise Tallon As Chief Financial Officer; Des Fitzgerald Will Continue As Interim CFO Until Late July 2024; Reiterates Financial Guidance And Intend To Achieve ~$20M Of Annualized Run-Rate EBITDASO On Annualized Revenues Of ~$75M By Q2 2025
Trinity Biotech宣佈任命Louise Tallon擔任首席財務官; Des Fitzgerald將繼續擔任臨時首席財務官，直至2024年7月晚些時候;重申財務指引，並打算在2025年第二季度實現年化營收約爲$ 7500萬的年化EIBTDASO的約2000萬元
Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of Louise Tallon as Chief Financial Officer ("CFO"). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024.
Trinity Biotech plc（NASDAQ：TRIB）是一家商業化生物技術公司，專注於人類診斷和糖尿病管理解決方案，包括穿戴式生物傳感器。今天宣佈任命Louise Tallon擔任首席財務官（"CFO"）。Louise將於2024年8月加入Trinity Biotech。自2023年12月以來擔任臨時首席財務官的Des Fitzgerald將繼續擔任臨時首席財務官，直至2024年7月晚些時候。
Commenting on the appointment, John Gillard, CEO of Trinity Biotech plc, said "We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment. This skill set, combined with her extensive experience in the life sciences product commercialisation industry, will elevate the continued development of the organisation as we continue to deliver on our corporate strategy of delivering our comprehensive transformation plan and introducing our next generation continuous glucose monitor, or CGM, to global markets. With the CFO transition we also reiterate our financial guidance and intend to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025."
Trinity Biotech plc的首席執行官John Gillard在談到任命時表示:"我們很高興歡迎Louise加入，她在動態環境中實現轉型和增長方面擁有豐富的經驗。這種技能集與她在生命科學產品商業化行業廣泛的經驗相結合，將提高該組織的持續發展，因爲我們繼續按照我們的企業策略交付我們的全面轉型計劃並推向全球市場我們的下一代連續葡萄糖監測器或CGm。隨着首席財務官的過渡，我們還重申了我們的財務指引，並打算在2025年第二季度實現年化營收約爲$7500萬的年化EBITDASO的約2000萬元。"
譯文內容由第三人軟體翻譯。